A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent (PEPCAD)
A Multicenter, Randomized, Active Controlled Clinical Study to Evaluate the Safety and Efficacy of the Treatment of In-stent Restenosis Lesion by Paclitaxel-eluting PTCA- Balloon Catheter Versus Paclitaxel-eluting Stent
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Fuwai CVD Hospital of Chinese Academy of Medical Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Related to patients
- Patients with stable angina, unstable angina, old myocardial infarction or proven asymptomatic ischemia
- Restenosis after the first stent implant
- Patients who can receive any kind of coronary revascularization (including balloon angioplasty, stent implantation or coronary artery bypass grafting)
- Patient aged 18-80 (including 18 and 80)
- Female patients of childbearing age in the study period shall not be pregnant or protocol to be pregnant, it is suggested that patients shall take sufficient contraception measures till (including) the follow-up visit of month 9
- Patients who agree to accept the angiography follow-up visits of month 9
- Patients who agree to accept the clinical visits at Day 30, Month 6 and Month 12
- Patients can understand the study objectives psychologically and linguistically and show the sufficient compliance to the study protocol. Patients present acceptance of the risks and benefits described in the informed consent form.
Related to lesion
- Drug-eluting stent restenosis: Type Mehran I, Type II and Type III; the reference blood vessel diameter is 2.5 mm-4.0 mm, length ≤30mm
- Before surgery, stenosis diameter must be ≥70% or ≥50% and accompanied by ischemia
- The distance between other lesion requires interventional therapy and the target lesion must be >10mm
- In the stent group, up to two paclitaxel drug stents are permitted to be implanted in series
Exclusion Criteria:
Related to patients
- Patients with myocardial infarction within one week
- Patients with severe congestive heart failure or NYHA IV severe heart failure
- Patients with severe valvular heart disease
- Female patients in pregnancy or lactation
- Patients with the life expectancy not exceeding 1 year or the factors causing difficult clinical follow-up visits
- Patients with hemorrhagic tendency, prohibited to take anticoagulants or antiplatelet drugs
- Patients with stroke within 6 months before the surgery
- Patients taking part in any other clinical tests
- Existing sever renal failure (GFR<30ml/min) or the history, so not meeting the conditions of angiography
- Patients with cardiac transplantation
- Patients not included for other reasons from the investigators
Related to lesion
- Evidence of extensive thrombus in target blood vessel before the intervention
- Percutaneous coronary intervention for many in-stent restenosis lesions in same artery
- 3-vessel disease that all need to be intervented
- In bifurcation lesions, branch open blood vessel diameter ≥2.5mm
- Percutaneous coronary intervention of venous graft
- Entire shut of Grade TIMI 0 blood flow (Type Mehran IV stenosis)
- Open lesion at left primary and within 2mm
Related to concomitant therapy
- Patients cannot tolerate aspirin and/or clopidogrel, patients with the history of neutrocytopenia or thrombocytopenia, or patients with severe hypohepatia and prohibited to take clopidogrel
- Patients known allergic to paclitaxel
- Patients with the history of leucopenia (numeration of leukocytes <3x109/L, exceeding 3 days), neutrocytopenia (ANC<1000 neutrocytes/mm3, exceeding 3 days) or thrombocytopenia (<100,000 platelets/mm3
- Patients with the history of peptic ulcer or gastrointestinal hemorrhage in the past 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SeQuent® Please
Paclitaxel Drug-eluting Coronary Artery Balloon Catheter
|
SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
Other Names:
|
|
Active Comparator: Taxus Liberte
Paclitaxel Drug-eluting Coronary Stent and Conveying System
|
Taxus Liberte with a length of 8mm,12mm,16mm,20mm and 24mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Late lumen loss in segment section at M9
Time Frame: One year
|
To measure the diameter loss in segment restenosis of the target lesion vessel by using angiography
|
One year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Success rate of the interventional therapy
Time Frame: Two year
|
To compare the successful treatment of coronary artery stent restenosis intervention between Paclitaxel release PTCA balloon and Taxus® Liberte, including apparatus success, lesion success and clinical success
|
Two year
|
|
Outcomes of clinical follow-up visits for drug stent versus drug balloon
Time Frame: Two year
|
|
Two year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Runlin Gao, Prof., Fuwai CVD Hospital of Chinese Academy of Medical Sciences
Publications and helpful links
General Publications
- Xu B, Qian J, Ge J, Wang J, Chen F, Chen J, Wei M, Chen Y, Yang Y, Gao R; PEPCAD China ISR investigators. Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis. Catheter Cardiovasc Interv. 2016 Mar;87 Suppl 1:624-9. doi: 10.1002/ccd.26401. Epub 2016 Jan 17.
- Xu B, Gao R, Wang J, Yang Y, Chen S, Liu B, Chen F, Li Z, Han Y, Fu G, Zhao Y, Ge J; PEPCAD China ISR Trial Investigators. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. JACC Cardiovasc Interv. 2014 Feb;7(2):204-211. doi: 10.1016/j.jcin.2013.08.011.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AE-V-S-1001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.